Friedreich's ataxia: the vicious circle hypothesis revisited

1741-7015-9-1121741-7015 Opinion Friedreich's ataxia: the vicious circle hypothesis revisited BayotAurélienaurelien.bayot@inserm.fr SantosRenatasantos.renata@ijm.univ-paris-diderot.fr CamadroJean-Michelcamadro.jean-michel@ijm.univ-paris-diderot.fr RustinPierrepierre.rustin@inserm.fr

Inserm, U676, Physiopathology and Therapy of Mitochondrial Diseases Laboratory, CHU - Hôpital Robert Debré, 48, boulevard Sérurier, F-75019 Paris, France

Faculté de médecine Denis Diderot, Université Paris-Diderot, IFR02, 16, rue Henri Huchard, F-75018, Paris, France

Institut Jacques Monod (UMR 7592 CNRS-Université Paris-Diderot), Mitochondria, Metals and Oxidative Stress Laboratory, Bâtiment Buffon - 15, rue Hélène Brion, F-75205 Paris, Cedex 13, France

BMC Medicine 1741-7015 2011 9 1 112 http://www.biomedcentral.com/1741-7015/9/112 10.1186/1741-7015-9-11221985033 17520111110201111102011 2011Bayot et al; licensee BioMed Central Ltd.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Friedreich's ataxia, the most frequent progressive autosomal recessive disorder involving the central and peripheral nervous systems, is mostly associated with unstable expansion of GAA trinucleotide repeats in the first intron of the FXN gene, which encodes the mitochondrial frataxin protein. Since FXN was shown to be involved in Friedreich's ataxia in the late 1990s, the consequence of frataxin loss of function has generated vigorous debate. Very early on we suggested a unifying hypothesis according to which frataxin deficiency leads to a vicious circle of faulty iron handling, impaired iron-sulphur cluster synthesis and increased oxygen radical production. However, data from cell and animal models now indicate that iron accumulation is an inconsistent and late event and that frataxin deficiency does not always impair the activity of iron-sulphur cluster-containing proteins. In contrast, frataxin deficiency appears to be consistently associated with increased sensitivity to reactive oxygen species as opposed to increased oxygen radical production. By compiling the findings of fundamental research and clinical observations we defend here the opinion that the very first consequence of frataxin depletion is indeed an abnormal oxidative status which initiates the pathogenic mechanism underlying Friedreich's ataxia.

Background

Friedreich's ataxia (FA), the most prevalent form of autosomal recessive cerebellar ataxia in Caucasians, is characterised by progressive ataxia and dysarthria 1 . The symptoms usually become apparent around puberty, although onset may occur much later in life (> 60 years old). The neurological features include sensory neuropathy, deep sensory impairment, signs of pyramidal tract involvement and progressive cerebellar dysfunction. The nonneurological manifestations vary, but among them hypertrophic cardiomyopathy is common. Diabetes mellitus occurs in approximately one-third of FA patients 1 . FA therefore appears to be a rather heterogeneous disorder. In the vast majority of cases, it is caused by a GAA trinucleotide repeat expansion in the first intron of the frataxin-encoding gene (FXN), which results in decreased gene expression and partial loss of function of the frataxin protein in the mitochondrial matrix 2 . Frataxin has been shown to interact with the iron-sulphur cluster (ISC) assembly machinery 3 (Figure 1). Frataxin loss of function therefore can result in ISC-containing protein (ISP) deficiency, decreasing aconitase and mitochondrial respiratory chain activity 4 , but it also results in hypersensitivity to oxidative stress 5 6 and accumulation of iron in affected organs 7 .

Figure 1

Frataxin function in the mitochondria

Frataxin function in the mitochondria. The schema illustrates the iron-sulphur cluster (ISC) biosynthesis machinery present in the mitochondrial matrix encompassing the ISCU-NFS1 protein complex associating glutaredoxin 5 (GLRX5) with the frataxin protein. It makes use of iron possibly delivered by the mitochondrial ferritin to synthesize ISC also distributed among several of the mitochondrial proteins (including several membrane-bound respiratory chain components, complexes I, II and III and the matrix-soluble aconitase). In addition to its role in the biogenesis of ISC, the frataxin protein might be associated with ISC after their synthesis. The detoxifying role of vitamin E in the mitochondrial inner membrane is also indicated. ISP, ISC-containing protein; mt, mitochondrial.

Except perhaps for gene-targeting therapies, to develop rational treatments for FA, we need to better elucidate the actual mechanism underlying the disease pathophysiology. On the basis of recent studies of various conditions in many different organisms (from microorganisms to humans), including human diseases originating from mutations in genes functionally related to FXN, we tried to reconcile the various pathogenic manifestations resulting from frataxin depletion and argue for a prominent and early role of impaired responses to oxidative insults in FA.

The vicious circle hypothesis

The cellular consequences of frataxin loss of function were initially described as faulty iron handling, impaired ISC synthesis and increased reactive oxygen species production 4 . We and others hypothesized that a vicious circle might link these three abnormalities (Figure 2A) and that targeting any of the three would consequently be as effective in slowing disease progression as targeting one or both of the other two abnormalities.

Figure 2

The vicious circle hypothesis revisited in Friedreich's ataxia

The vicious circle hypothesis revisited in Friedreich's ataxia. (A) According to the vicious circle hypothesis, frataxin depletion results in impaired iron-sulphur cluster synthesis and/or stability with intramitochondrial accumulation of reactive iron. Reactive iron promotes Fenton chemistry, producing superoxide and hydrogen peroxide, which in turn destroys more iron-sulphur clusters. ISC, iron-sulphur cluster. (B) In frataxin-depleted cells, deficient signalling of antioxidant defences sensitises the frataxin-free iron-sulphur clusters to reactive oxygen species. This antioxidant sensitisation process results in intramitochondrial iron accumulation, mostly as amorphous nonreactive precipitates. ROS, reactive oxygen species.

Frataxin deficiency is not consistently associated with impaired iron-sulphur cluster synthesis or stability

In 1997, we reported the deficiency of ISP activity as the signature of frataxin depletion in humans 4 . Most tissues investigated, including skeletal muscle, lymphocytes and skin fibroblasts, were spared, however, and the deficiency was observed only in the heart and reported later in postmortem brain tissue. Since that initial observation, a series of remarkable works by Lill's group 3 carried out on frataxin-lacking yeast have conclusively demonstrated that frataxin has the capacity to participate in ISC synthesis through its interaction with the biosynthesis machinery.

However, in a number of conditions, frataxin depletion was not found to be associated with decreased activity of ISPs. In particular, as noted above, studies of frataxin-depleted cultured human skin fibroblasts, circulating lymphocytes or lymphoblastoid cell lines from FA patients found no decrease in ISPs 4 , although the frataxin content was < 20% of the control value. Nevertheless, these cells have a phenotype that responds abnormally to a whole range of oxidative insults 6 8 9 . Studies of Saccharomyces cerevisiae also identified conditions under which, even in the total absence of frataxin, a significant synthesis of ISCs took place 10 . Thus, ISCs in frataxin-lacking S. cerevisiae were still synthesized when the cultures were protected from oxygen exposure (> 55% for 4Fe-4S clusters as compared to control yeast) 10 . This established that the function of frataxin in ISC synthesis and/or stability is dispensable under these conditions, as it is in a number of organisms, including Archaea and Gram-positive bacteria 11 , and might be related to protection from oxygen-derived components.

Intramitochondrial iron accumulation is a late event

As early as 1997, the intramitochondrial accumulation of iron was reported in the frataxin-lacking yeast, which led to the suggestion that frataxin regulates the export of iron from the mitochondrial matrix 12 . This echoed the even earlier observation of iron accumulation in postmortem human brain tissue 7 . Because reduced iron readily triggers deleterious Fenton chemistry, we and others have proposed that iron could be instrumental in the pathophysiological process that results in FA 13 . However, except for some circumstantial reports 5 , attempts to detect significant mitochondrial iron accumulation in frataxin-depleted human fibroblasts and lymphoblasts, as well as changes in mitochondrial labile (reactive) iron, have failed 14 . Mitochondrial iron accumulates in frataxin-depleted cells only as a consequence of severely diminished ISC synthesis, resulting in amorphous, nonreactive, intramitochondrial precipitates of nanoparticles of ferric phosphate 15 . Accordingly, in mouse tissues lacking frataxin, mitochondrial iron deposition is a late event that follows the loss of ISPs 16 . Together these data suggest that mitochondrial iron accumulation is not an instrumental factor in the early steps of FA pathogenesis.

Frataxin depletion does not cause overproduction of superoxides

On the basis of the putative respiratory chain impairment and/or the iron-associated Fenton chemistry presumably resulting from iron mishandling, it has been inferred that frataxin depletion should result in overproduction of oxidant species. This inference was supported by the report of increased oxidative insult to DNA in FA patients 17 . However, under a number of conditions, no increase in oxidative species could be detected, and the mitochondria from frataxin-depleted cells (that is, fibroblasts) did not significantly produce more superoxides (assessed using the MitoSOX Red reagent; Invitrogen, Carlsbad, CA, USA than control cells, and targeting superoxides in frataxin-depleted human cells using Mn(III) tetrakis (4-benzoic acid) porphyrin chloride failed to restore a normal phenotype in these cells (P Rustin, unpublished data).

Frataxin deficiency consistently results in hypersensitivity to oxygen radicals

Numerous studies using various models have established that partial or complete frataxin deficiency results in varying degrees of respiratory chain impairment. Superoxide production by the mitochondria is mostly proportional to the electron flow and to the reduction of critical components of the chain, whereas superoxide elimination essentially depends on superoxide dismutase activity. The very severe impairments in respiratory chain and Krebs cycle activity associated with the absence of frataxin presumably result in decreased superoxide production. Underestimation of the consequences of complete frataxin deficiency has led to the apparently paradoxical conclusion that oxidative stress may not play a major role in FA pathology 18 . In contrast, in affected human tissues and a number of FA models, respiratory chain activity is only partially affected and the superoxide production machinery is therefore largely intact. In human fibroblasts with low frataxin content, we found a slight but consistent (< 30%) elevation in basal superoxide dismutase activity 9 , indicating that the oxidative status might be slightly abnormal, at least under conditions where the respiratory chain is fully active 19 . Similarly, in contrast to mice lacking frataxin 18 , mice with partial loss of frataxin show increased signs of lipoperoxidation 20 .

Studies of the antioxidant pools in frataxin-depleted cultured human cells have shown significant decreases in reduced glutathione along with actin stress fibre disorganization 21 , but this reduction in antioxidant pools have little or no impact on the cells under basal conditions. However, these cells and their iron-sulphur proteins have exquisite sensitivity to a wide range of experimental oxidative insults 9 , which often trigger rapid apoptosis 5 6 8 . This hypersensitivity was found in all frataxin-deficient cell types and organisms independently of abnormalities in mitochondrial ISP or iron content (Table 1). It was observed in connection with endogenous insults (respiratory chain blockade) and exogenous insults (various chemicals that generated oxidant species) as well. These findings suggest impairment of a set of antioxidant defences as opposed to one specific enzyme. Accordingly, impaired signalling of phase II antioxidant defences has been observed in frataxin-depleted human cells 9 .

Table 1

Consequences of frataxin depletion in various organisms^a

Organism

Increased ROS production/low glutathione

Increased peroxidation products

Hypersensitivity to oxidative insults

Loss of ISP activity

Mitochondrial iron overload

References

Saccharomyces

cerevisiae yeast

+/++

+++

+++

+++

Arabidopsis

thaliana plant

n.d.

+++

+++

Caenorhabditis

elegans worm

n.d.

+++

+++

n.d.

Drosophila melanogaster fly

(+)

n.d.

+++

+++

n.d.

Mus musculus mouse (humanised)

n.d.

+++

n.d.

+++

Homo sapiens

heart

n.d.

+++

Homo sapiens lymphoblasts

n.d.

+++

Homo sapiens skin fibroblasts

+++

^aROS: reactive oxygen species; ISP: iron-sulphur cluster-containing protein; +++: hallmark of the disease; ++: present in most cases; +: present only in a subset of patients or late in the course of the disease; (+): reported occasionally; -: usually absent; n.d., not determined.

This impairment is related to abnormalities in the nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor, which may result from disorganization of the actin stress filaments and abnormalities in the redox status of frataxin-deficient cells 9 . Concomitant impairments in related signalling pathways for mitochondrial components in response to the abnormal redox status of frataxin-depleted cells have also been reported 22 .

Lessons from clinical practice

Interestingly, myopathy without ataxia associated with impaired ISC synthesis was described recently 23 . This condition is due to mutation in the gene encoding the ISC scaffold protein (ISCU) in which differential splicing among tissues largely explains the tissue specificity 24 . Although recent data from Isaya's group 25 show that two frataxin isoforms do exist and have distinct functional properties regarding iron storage and/or ISC synthesis 25 , expression of the protein appears widespread in the organism, and both isoforms are supposedly similarly affected by GAA expansion in the gene. Accordingly, frataxin loss of function appears to be widespread in FA patients. Yet, the consequences are mostly observed in the brain and the heart, and primary myopathy is not a consistent or frequent feature of this disease 26 .

Because frataxin has been reported to interact directly with the NFS1-ISCU protein complex during ISC biosynthesis 3 (Figure 1), a certain level of overlap might be predicted, at least in tissues where the NFS1 gene mutation causes a phenotype. The absence of such overlap is thus not easy to reconcile with the fact that the two proteins are involved in the same step of ISC biosynthesis in vivo (Table 2). A similar observation stands true regarding glutaredoxin 5 (an assembly factor for cellular ISC) 27 (Figure 1), as a mutation in the exon 1 of the GLRX5 gene, putatively leading to a deleterious splicing defect, results in sideroblastic anaemia without ataxia and no overlap with the FA phenotype 28 .

Table 2

Cardinal clinical symptoms associated with deficiencies in frataxin, vitamin E, ABCB7 (mitochondrial iron overload), GLRX5 (impaired ISC synthesis) and ISCU (impaired ISC synthesis)^a

Clinical symptoms

Frataxin deficiency

Vitamin E deficiency

ABCB7 deficiency

GLRX5 deficiency

ISCU deficiency

Ataxia

+++

Cardiomyopathy

Diabetes mellitus

(+)

Myopathy

(+)

+++

Sideroblastic anaemia

+++

+++

Hepatosplenomegaly

Lactic acidosis

(+)

+++

^a+++: hallmark of the disease; ++: present in most cases; +: present only in a subset of patients or late in the course of the disease; (+): reported occasionally; -: usually absent. Disease symptoms shared with Friedreich's ataxia are represented using a similar grey colour.

Accumulation of mitochondrial iron and decreased cytosolic iron associated with the ABCB7 mutations, mostly missense mutations changing amino acids in the C-terminal end of the transmembrane domain of the protein, results in cerebellar ataxia, albeit different from FA, and includes sideroblastic anaemia 29 30 . This ABC transporter is involved in ISC export from the mitochondria to the cytosol 31 (Figure 1). Yeast studies showed preserved mitochondrial ISP activity despite intramitochondrial iron accumulation 32 . However, as with frataxin depletion, hypersensitivity to oxidative stress has been reported in ABCB7 mutants 33 , suggesting that a common mechanism resulting in impaired handling of reactive oxygen species may be involved at some point in both types of ataxia.

Finally, the striking similarity of the symptoms in vitamin E deficiency and frataxin deficiency 34 , both encompassing cerebellar ataxia with inconsistent cardiomyopathy 35 , suggests similar cellular consequences of frataxin and vitamin E depletion. Vitamin E acts chiefly as a membrane antioxidant, in concert with ubiquinone, and plays no role in ISC biosynthesis 36 (Figure 1).

Thus, a comparison of the various clinical phenotypes (Table 2) is consistent with, though obviously not proving per se, the view 37 emerging from studies of various situations and models (Table 1) that frataxin depletion results primarily in increased sensitivity to oxidative stress (Figure 2B).

Discussion

Since the discovery of the gene mutation responsible for FA, major advances have been made in our understanding of this disease, despite the difficulties encountered in gaining access to affected tissue in humans, especially the brain. In particular, FA can now be regarded as a true mitochondrial disease similar to a number of mitochondrial ataxias due to different genetic mechanisms 38 . The respective roles of deficient respiratory chain function (decreased ATP synthesis) and impaired oxygen handling in the clinical course remain to be determined in most of these diseases. However, in the case of FA, impaired oxygen handling appears to be crucial in the cascade of events determining the onset of the symptoms and fits the progressive degenerative course of the disease. Obviously, emphasizing the role of hypersensitivity to oxygen in triggering FA does not shed any light on the undisputed contributory role of frataxin in ISC synthesis and/or stability 39 40 . Yet, available data indicate that both processes can be dissociated under a number of conditions in different models, including humans. Unfortunately, the molecular mechanism linking frataxin function to this hypersensitivity to oxygen is not yet established, similarly to the exact role of the protein in ISC synthesis, which is still a matter of intense debate. Frataxin has been claimed to activate import of iron into the cell 41 and to chaperone iron 42 43 or ISC 44 45 to act as a partner for 46 or inhibitor of 47 ISC synthesis. How frataxin shortage in mitochondria results in impaired signalling of antioxidant defences in the cell cytosol has yet to be elucidated. So far, it is only known that frataxin deficiency in human cells interferes with the redox status of the cell 21 , thus presumably impairing the function of the Nrf2 9 and possibly PGC1α 48 transcription factors.

Hypersensitivity to oxidant insult is a consistent feature of human cells 5 6 8 9 and animal models 49 50 with low frataxin content (Table 1). This observation should not be confused with an increased production of oxidative species and peroxidised products, yet has frequently been observed and reported (in about 100 papers), which either may not be observed, especially if respiratory chain activity is too severely depressed, or may not be accumulated if produced at low levels. Finally, in FA patients, oxidative markers and/or antioxidant enzymes are also modified in response to frataxin depletion 17 51 52 53 54 , which was found to be an incentive to trial antioxidant molecules in this disease 55 56 57 .

Several ongoing clinical trials are evaluating interventions that target various steps in the pathogenic process: impaired frataxin synthesis, oxidative insults and iron accumulation 58 . Idebenone, a short-chain coenzyme Q10 homologue, has initially been reported to be effective (at a dosage of 5 to 20 mg/kg/day) in preventing cardiac hypertrophy in most patients 59 , while having (at this dosage) little or no effect on the neurological abnormalities 19 . Interestingly, while studying endomyocardial biopsies from a young patient with FA before and after idebenone treatment, we found that the drug largely restored the activity of ISPs 60 . Since idebenone is a potent antioxidant, this finding suggests that loss of ISP activity in vivo is due chiefly to increased oxidative degradation, and not to impaired synthesis, of these proteins. In this context, we may wonder why antioxidant therapies (for example, idebenone, coenzyme Q10) have such a limited impact on the neurological disease expression and/or course in FA. Indeed, recent widely based studies carried out in Europe (the MICONOS (Mitochondrial Protection with Idebenone in Cardiac Or Neurological Outcome Study) trial, comprising 232 patients with 162 on idebenone, mostly adults, at 13 centres; Andrews WT unpublished communication from the FARA meeting in Strasbourg, France, June 2011) and in the United States (the IONIA (Idebenone Effects on Neurological International Cooperative Ataxia Rating Scale Assessments) trial; 70 patients) 61 did not confirm the previous reports of the beneficial effects of idebenone in this disease. However, as mentioned by the initiators of the MICONOS trial themselves, the results of the available studies, even if not statistically significant, still indicate a trend toward a positive effect of idebenone (as compared to placebo). A possibly underestimated factor that might prevent the results of such studies from reaching statistical significance in their relatively small cohorts is the occurrence of responsive and unresponsive patients reported in early FA patients treated with idebenone 59 , as has been true for a number of other mitochondrial diseases 62 . Conversely, the negative conclusion of these latter trials, mainly carried out with adults, might be related to the age of the patients. Accordingly, even more recently this year, an open-label extension of the IONIA study (IONIA-E trial; 68 patients) concluded that idebenone may offer a therapeutic benefit to paediatric FA patients by stabilizing overall neurological function and improving fine motor skills and speech 63 . There is no definite answer to this question; however, a number of indications suggest that intervention might be much too late. Indeed, it is a frequent observation in neurological diseases caused by gene mutations (nuclear or mitochondrial) encoding mitochondrial proteins that symptoms are subsequent to extended auto-amplifying cell death resulting from mitochondrial dysfunction rather than from mitochondrial dysfunction itself (for example, ATP decrease, metabolic blockade). This can be observed in a number of animal models where early, partial or tissue-specific inactivation of such genes (Tfam and Aif) results in a delayed neurological phenotype despite early mitochondrial dysfunction 64 65 . Thus, Tfam-depleted neurons, despite severe respiratory chain deficiency, are viable for one month in the mouse without showing signs of the neurodegeneration which precedes neurological symptoms 64 . Similarly, despite early detectable complex I deficiency in the brain, the Harlequin mouse with depleted Aif protein only manifests significant symptoms after several weeks or months of life in most individuals 65 . Likewise, frataxin gene loss of function in FA, although it occurs early in embryogenesis, has a neurological impact several years later. Thus, the onset of neurological symptoms associated with impaired mitochondrial function might follow the loss of neurons rather than mitochondrial dysfunction per se. Accordingly, any therapy aimed at counteracting mitochondrial dysfunction, regardless of the strategy used (modulating gene expression, gene therapy or pharmacological therapy) would be best tested if it preceded disease initiation.

Conclusions

The present compilation of recent data on the pathological cascade in FA argues in favour of continuing experimentation with antioxidants in FA, despite the deceptive results of the most recent idebenone clinical trials, but care should be taken to focus on selected cohorts of patients within the presumed therapeutic window. Additional therapeutic strategies aimed at counteracting hypersensitivity to reactive oxygen species should also be developed. In keeping with this, pioglitazone, a peroxisome proliferator-activated receptor γ ligand that improves natural antioxidant defences (including frataxin), is presently being under trial in our hospital in France (two-year phase III trial ending in 2013). Other approaches aimed at increasing frataxin levels, histone deacetylase inhibitors 66 and nonerythropoietic derivatives of erythropoietin 67 may also result in decreased cellular hypersensitivity to reactive oxygen species, as a direct correlation has been shown between this hypersensitivity and the actual level of frataxin, from depletion to overexpression 68 . We hope that some of these promising compounds will prove effective in halting the progression of FA.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

All authors participated in the conception of this opinion paper, which was written by PR. All authors read and approved the final manuscript.

Acknowledgements

We are grateful to the organizations for Friedreich's ataxia patients (BabelFAmily, Ataxia UK, ACHAF, AISA, APAHE, FASI, FARA, RevaMoto and AFAF) and to the Leducq Foundation for financial support.

Diagnosis and treatment of Friedreich ataxia: a European perspectiveSchulzJBBoeschSBürkKDürrAGiuntiPMariottiCPoussetFSchölsLVankanPPandolfoMNat Rev Neurol2009522223410.1038/nrneurol.2009.2619347027Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansionCampuzanoVMonterminiLMoltòMDPianeseLCosséeMCavalcantiFMonrosERodiusFDuclosFMonticelliAZaraFCañizaresJKoutnikovaHBidichandaniSIGelleraCBriceATrouillasPDe MicheleGFillaADe FrutosRPalauFPatelPIDi DonatoSMandelJLCocozzaSKoenigMPandolfoMScience19962711423142710.1126/science.271.5254.14238596916An interaction between frataxin and Isu1/Nfs1 that is crucial for Fe/S cluster synthesis on Isu1GerberJMühlenhoffULillREMBO Rep2003490691110.1038/sj.embor.embor918132635612947415Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxiaRötigAde LonlayPChretienDFouryFKoenigMSidiDMunnichARustinPNat Genet19971721521710.1038/ng1097-2159326946The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosisWongAYangJCavadiniPGelleraCLonnerdalBTaroniFCortopassiGHum Mol Genet1999842543010.1093/hmg/8.3.4259949201Disabled early recruitment of antioxidant defenses in Friedreich's ataxiaChantrel-GroussardKGeromelVPuccioHKoenigMMunnichARötigARustinPHum Mol Genet2001102061206710.1093/hmg/10.19.206111590123Iron, brain ageing and neurodegenerative disordersZeccaLYoudimMBRiedererPConnorJRCrichtonRRNat Rev Neurosci2004586387315496864Manganese superoxide dismutase induction by iron is impaired in Friedreich ataxia cellsJiralerspongSGeBHudsonTJPandolfoMFEBS Lett200150910110510.1016/S0014-5793(01)03140-411734214Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxiaPaupeVDassaEPGoncalvesSAuchèreFLönnMHolmgrenARustinPPLoS One20094e425310.1371/journal.pone.0004253261776219158945Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxiaBulteauALDancisAGareilMMontagneJJCamadroJMLesuisseEFree Radic Biol Med2007421561157010.1016/j.freeradbiomed.2007.02.01417448903Friedreich's ataxia protein: phylogenetic evidence for mitochondrial dysfunctionGibsonTJKooninEVMuscoGPastoreABorkPTrends Neurosci19961946546810.1016/S0166-2236(96)20054-28931268Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxinBabcockMde SilvaDOaksRDavis-KaplanSJiralerspongSMonterminiLPandolfoMKaplanJScience19972761709171210.1126/science.276.5319.17099180083Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced injury in vitroRustinPMunnichARötigABiofactors1999924725110.1002/biof.552009022010416037Friedreich's ataxia, no changes in mitochondrial labile iron in human lymphoblasts and fibroblasts: a decrease in antioxidative capacity?SturmBBistrichUSchranzhoferMSarseroJPRauenUScheiber-MojdehkarBde GrootHIoannouPPetratFJ Biol Chem20052806701670810.1074/jbc.M40871720015615730Evidence that yeast frataxin is not an iron storage protein in vivoSeguinASutakRBulteauALGarcia-SerresROddouJLLefevreSSantosRDancisACamadroJMLatourJMLesuisseEBiochim Biophys Acta2010180253153820307653Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe-S enzyme deficiency followed by intramitochondrial iron depositsPuccioHSimonDCosséeMCriqui-FilipePTizianoFMelkiJHindelangCMatyasRRustinPKoenigMNat Genet20012718118610.1038/8481811175786Oxidative stress in patients with Friedreich ataxiaSchulzJBDehmerTSchölsLMendeHHardtCVorgerdMBurkKMatsonWDichgansJBealMFBogdanovMBNeurology2000551719172111113228Friedreich ataxia: the oxidative stress paradoxSeznecHSimonDBoutonCReutenauerLHertzogAGolikPProcaccioVPatelMDrapierJCKoenigMPuccioHHum Mol Genet20051446347415615771Friedreich's ataxia: molecular mechanisms, redox considerations, and therapeutic opportunitiesSantosRLefevreSSliwaDSeguinACamadroJMLesuisseEAntioxid Redox Signal20101365169010.1089/ars.2009.3015292478820156111GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathologyAl-MahdawiSPintoRMVarshneyDLawrenceLLowrieMBHughesSWebsterZBlakeJCooperJMKingRPookMAGenomics20068858059010.1016/j.ygeno.2006.06.015284293016919418Actin glutathionylation increases in fibroblasts of patients with Friedreich's ataxia: a potential role in the pathogenesis of the diseasePastoreATozziGGaetaLMBertiniESerafiniVDi CesareSBonettoVCasoniFCarrozzoRFedericiGPiemonteFJ Biol Chem2003278425884259510.1074/jbc.M30187220012915401PGC-1α down-regulation affects the antioxidant response in Friedreich's ataxiaMarmolinoDMantoMAcquavivaFVergaraPRavellaAMonticelliAPandolfoMPLoS One20105e1002510.1371/journal.pone.0010025285092220383327Splice mutation in the iron-sulfur cluster scaffold protein ISCU causes myopathy with exercise intoleranceMochelFKnightMATongWHHernandezDAyyadKTaivassaloTAndersenPMSingletonARouaultTAFischbeckKHHallerRGAm J Hum Genet20088265266010.1016/j.ajhg.2007.12.012242721218304497Differences in RNA processing underlie the tissue specific phenotype of ISCU myopathySanakerPSToompuuMHoganVEHeLTzoulisCChrzanowska-LightowlersZMTaylorRWBindoffLABiochim Biophys Acta2010180253954420206689Normal and Friedreich ataxia cells express different isoforms of frataxin with complementary roles in iron-sulfur cluster assemblyGakhOBedekovicsTDuncanSFSmithDYBerkholzDSIsayaGJ Biol Chem2010285384863850110.1074/jbc.M110.14514420889968Friedreich's ataxia associated with mitochondrial myopathy: clinicopathologic reportGallagherCLWaclawikAJBeinlichBRHardingCOPauliRMPoirerJPandolfoMSalamatMSJ Child Neurol20021745345610.1177/08830738020170061212174969Deficiency of glutaredoxin 5 reveals Fe-S clusters are required for vertebrate haem synthesisWingertRAGallowayJLBarutBFoottHFraenkelPAxeJLWeberGJDooleyKDavidsonAJSchmidBPawBHShawGCKingsleyPPalisJSchubertHChenOKaplanJZonLITübingen 2000 Screen ConsortiumNature20054361035103910.1038/nature0388716110529The human counterpart of zebrafish <it>shiraz </it>shows sideroblastic-like microcytic anemia and iron overloadCamaschellaCCampanellaADe FalcoLBoschettoLMerliniRSilvestriLLeviSIolasconABlood20071101353135810.1182/blood-2007-02-07252017485548Mutation of a putative mitochondrial iron transporter gene (<it>ABC7</it>) in X-linked sideroblastic anemia and ataxia (XLSA/A)AllikmetsRRaskindWHHutchinsonASchueckNDDeanMKoellerDMHum Mol Genet1999874374910.1093/hmg/8.5.74310196363X-linked cerebellar ataxia and sideroblastic anaemia associated with a missense mutation in the <it>ABC7 </it>gene predicting V411LMaguireAHellierKHammansSMayABr J Haematol200111591091710.1046/j.1365-2141.2001.03015.x11843825Human ABC7 transporter: gene structure and mutation causing X-linked sideroblastic anemia with ataxia with disruption of cytosolic iron-sulfur protein maturationBekriSKispalGLangeHFitzsimonsETolmieJLillRBishopDFBlood2000963256326411050011Biophysical characterization of the iron in mitochondria from Atm1p-depleted <it>Saccharomyces cerevisiae</it>MiaoRKimHKoppoluUMEllisEAScottRALindahlPABiochemistry2009489556956810.1021/bi901110n275832419761223Mitochondrial ATP-binding cassette proteinsBurkeMAArdehaliHTransl Res2007150738010.1016/j.trsl.2007.03.00217656326Ataxia with vitamin E deficiency: update of molecular diagnosisDi DonatoIBianchiSFedericoANeurol Sci20103151151510.1007/s10072-010-0261-120464573Vitamin E deficiency ataxia with (744 del A) mutation on α-TTP gene: genetic and clinical peculiarities in Moroccan patientsMarzoukiNBenomarAYahyaouiMBiroukNElouazzaniMChkiliTBenlemlihMEur J Med Genet200548212810.1016/j.ejmg.2005.01.01415953402Vitamin E, antioxidant and nothing moreTraberMGAtkinsonJFree Radic Biol Med20074341510.1016/j.freeradbiomed.2007.03.024204011017561088Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical questionArmstrongJSKhdourOHechtSMFASEB J2010242152216310.1096/fj.09-14322220219987Mitochondrial ataxiasFinstererJCan J Neurol Sci20093654355319831121Maturation of iron-sulfur proteins in eukaryotes: mechanisms, connected processes, and diseasesLillRMühlenhoffUAnnu Rev Biochem20087766970010.1146/annurev.biochem.76.052705.16265318366324Structural bases for the interaction of frataxin with the central components of iron-sulphur cluster assemblyPrischiFKonarevPVIannuzziCPastoreCAdinolfiSMartinSRSvergunDIPastoreANat Commun201019510.1038/ncomms1097298216520981023Frataxin depletion in yeast triggers up-regulation of iron transport systems before affecting iron-sulfur enzyme activitiesMoreno-CermeñoAObisEBellíGCabiscolERosJTamaritJJ Biol Chem2010285416534166410.1074/jbc.M110.14944320956517Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevityGakhOParkSLiuGMacomberLImlayJAFerreiraGCIsayaGHum Mol Genet20061546747916371422The expression of human mitochondrial ferritin rescues respiratory function in frataxin-deficient yeastCampanellaAIsayaGO'NeillHASantambrogioPCozziAArosioPLeviSHum Mol Genet2004132279228810.1093/hmg/ddh23215282205Molecular control of the cytosolic aconitase/IRP1 switch by extramitochondrial frataxinCondòIMalisanFGucciniISerioDRufiniATestiRHum Mol Genet2010191221122910.1093/hmg/ddp59220053667Frataxin interacts functionally with mitochondrial electron transport chain proteinsGonzález-CaboPVázquez-ManriqueRPGarcía-GimenoMASanzPPalauFHum Mol Genet2005142091209810.1093/hmg/ddi21415961414Molecular details of the yeast frataxin-Isu1 interaction during mitochondrial Fe-S cluster assemblyCookJDKondapalliKCRawatSChildsWCMurugesanYDancisAStemmlerTLBiochemistry2010498756876510.1021/bi1008613300594020815377Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscSAdinolfiSIannuzziCPrischiFPastoreCIamettiSMartinSRBonomiFPastoreANat Struct Mol Biol20091639039610.1038/nsmb.157919305405Functional genomic analysis of frataxin deficiency reveals tissue-specific alterations and identifies the PPARγ pathway as a therapeutic target in Friedreich's ataxiaCoppolaGMarmolinoDLuDWangQCnopMRaiMAcquavivaFCocozzaSPandolfoMGeschwindDHHum Mol Genet2009182452246110.1093/hmg/ddp183269469319376812Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a <it>Drosophila </it>model of Friedreich ataxiaShidaraYHollenbeckPJJ Neurosci201030113691137810.1523/JNEUROSCI.0529-10.2010294315320739558Reduction of <it>Caenorhabditis elegans </it>frataxin increases sensitivity to oxidative stress, reduces lifespan, and causes lethality in a mitochondrial complex II mutantVázquez-ManriqueRPGonzález-CaboPRosSAzizHBaylisHAPalauFFASEB J20062017217416293572Glutathione in blood of patients with Friedreich's ataxiaPiemonteFPastoreATozziGTagliacozziDSantorelliFMCarrozzoRCasaliCDamianoMFedericiGBertiniEEur J Clin Invest2001311007101110.1046/j.1365-2362.2001.00922.x11737244Antioxidant enzymes in blood of patients with Friedreich's ataxiaTozziGNuccetelliMLo BelloMBernardiniSBellincampiLBalleriniSGaetaLMCasaliCPastoreAFedericiGBertiniEPiemonteFArch Dis Child20028637637910.1136/adc.86.5.376175109111970939Friedreich's ataxia: oxidative stress and cytoskeletal abnormalitiesSparacoMGaetaLMSantorelliFMPassarelliCTozziGBertiniESimonatiAScaravilliFTaroniFDuyckaertsCFeleppaMPiemonteFJ Neurol Sci200928711111810.1016/j.jns.2009.08.05219748629Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathologyHaugenACDi ProsperoNAParkerJSFanninRDChouJMeyerJNHalwegCCollinsJBDurrAFischbeckKVan HoutenBPLoS Genet20106e100081210.1371/journal.pgen.1000812279951320090835Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary studyRustinPvon Kleist-RetzowJCChantrel-GroussardKSidiDMunnichARötigALancet199935447747910.1016/S0140-6736(99)01341-010465173Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxiaLodiRHartPERajagopalanBTaylorDJCrilleyJGBradleyJLBlamireAMMannersDStylesPSchapiraAHCooperJMAnn Neurol20014959059610.1002/ana.100111357949The use of antioxidants in Friedreich's ataxia treatmentRustinPExpert Opin Investig Drugs20031256957510.1517/13543784.12.4.56912665413Friedreich ataxia: an update on animal models, frataxin function and therapiesGonzález-CaboPLlorensJVPalauFMoltóMDAdv Exp Med Biol200965224726110.1007/978-90-481-2813-6_1720225031Idebenone and reduced cardiac hypertrophy in Friedreich's ataxiaHausseAOAggounYBonnetDSidiDMunnichARötigARustinPHeart20028734634910.1136/heart.87.4.346176706811907009Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trialRustinPBonnetDRötigAMunnichASidiDNeurology20046252452514872056A phase 3, double-blind, placebo-controlled trial of idebenone in Friedreich ataxiaLynchDRPerlmanSLMeierTArch Neurol20106794194710.1001/archneurol.2010.16820697044Genetic background influences mitochondrial function: modeling mitochondrial disease for therapeutic developmentBénitPEl-KhouryRSchiffMSainsard-ChanetARustinPTrends Mol Med20101621021710.1016/j.molmed.2010.03.00120382561Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension studyMeierTPerlmanSLRummeyCCoppardNJLynchDRJ NeurolLate-onset corticohippocampal neurodepletion attributable to catastrophic failure of oxidative phosphorylation in MILON miceSörensenLEkstrandMSilvaJPLindqvistEXuBRustinPOlsonLLarssonNGJ Neurosci2001218082809011588181The variability of the <it>Harlequin </it>mouse phenotype resembles that of human mitochondrial-complex I-deficiency syndromesBénitPGoncalvesSDassaEPBrièreJJRustinPPLoS One20083e320810.1371/journal.pone.0003208252768318791645Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxiaHermanDJenssenKBurnettRSoragniEPerlmanSLGottesfeldJMNat Chem Biol2006255155816921367Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptorSturmBHelmingerMSteinkellnerHHeidariMMGoldenbergHScheiber-MojdehkarBEur J Clin Invest20104056156510.1111/j.1365-2362.2010.02292.x20456483Overexpression of the yeast frataxin homolog (Yfh1): contrasting effects on iron-sulfur cluster assembly, heme synthesis and resistance to oxidative stressSeguinABayotADancisARogowska-WrzesinskaAAuchèreFCamadroJMBulteauALLesuisseEMitochondrion2009913013810.1016/j.mito.2009.01.00719460301Nitric oxide accumulation is required to protect against iron-mediated oxidative stress in frataxin-deficient Arabidopsis plantsMartinMColmanMJGómez-CasatiDFLamattinaLZabaletaEJFEBS Lett200958354254810.1016/j.febslet.2008.12.03919114041Overexpression of frataxin in the mitochondria increases resistance to oxidative stress and extends lifespan in <it>Drosophila</it>RunkoAPGriswoldAJMinKTFEBS Lett200858271571910.1016/j.febslet.2008.01.04618258192

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1741-7015/9/112/prepub